arrow
K

Konstantinos Liapis

democritus university of thrace
H指数:14
被引数:935

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high-risk myelodysplastic syndromes

腺苷能通路在高风险骨髓增生异常综合征患者对去甲基化药物耐药中的作用

2026-09-060
OAAI
Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model

西妥昔单抗单药治疗与利妥昔单抗为基础的治疗相比,可改善特发性多中心性Castleman病患者的无进展生存期;采用单臂Meta分析方法和广义线性混合模型对研究进行间接比较。

2025-12-050
OAAI
Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients

Hans-Based Cell of Origin 在弥漫大B细胞淋巴瘤患者中无预后意义:一项在326例接受RCHOP治疗的患者的单中心回顾性研究

2025-12-010
PRE
A ROLE FOR ADAR1 IN THE RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS)

ADAR1在对抗低甲基化剂(HMA)方面的高危骨髓增生异常综合征(HR-MDS)中的作用

2025-09-010
PRE
THE ROLE OF THE ADENOSINERGIC PATHWAY IN THE RESPONSE TO AZACYTIDINE IN HR-MDS PATIENTS PROGNOSIS-PREDICTIVE FACTORS OF RESPONSE TO TREATMENT

腺苷能通路在AZACYTIDINE对HR-MDS患者反应中的作用——治疗反应的预后预测因素

2025-09-010
PRE
Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration

拉瓦鲁zumab(Ravulizumab)能够稳定由抗-e和抗-Jka同种抗体引起的延迟性溶血性输血反应后的危及生命血管内溶血:首次成功给药。

2025-08-280
OAAI